Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of selinexor plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma (KMM 2205)
KCT0008467Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Amgen. Started Jul 2023; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0008467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008467.